[2-(4-氯苯氧基)乙基]肼 | 92307-08-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: [2-(4-氯苯氧基)乙基]肼
• 英文名称: 2-(-Chlorphenoxy)-ethylhydrazin
• 英文别名: 2-(4-Chlorophenoxy)ethylhydrazine
• CAS: 92307-08-9
• 化学式: C₈H₁₁ClN₂O
• mdl: MFCD05270100
• 分子量: 186.641
• InChiKey: VFIIPEQXYJLYCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  1,3-丙酮二羧酸二甲酯 、 [2-(4-氯苯氧基)乙基]肼 生成
  参考文献：
  名称：

  First in Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis

  摘要：

  We describe the design, synthesis, and optimization of first-in-class series of inhibitors of NADPH oxidase isoform 4 (Nox4), an enzyme implicated in several pathologies, in particular idiopathic pulmonary fibrosis, a life-threatening and orphan disease. Initially, several moderately potent pyrazolopyridine dione derivatives were found during a high-throughput screening campaign. SA R investigation around the pyrazolopyridine dione core led to the discovery of several double-digit nanomolar inhibitors in cell free assays of reactive oxygen species (ROS) production, showing high potency on Nox4 and Nox1. The compounds have little affinity for Nox2 isoform and are selective for Nox4/1 isoforms. The specificity of these compounds was confirmed in an extensive in vitro pharmacological profile, as well as in a counterscreening assay for potential ROS scavenging. Concomitant benefits are good oral bioavailability and high plasma concentrations in vivo, allowing further clinical trials for the potential treatment of fibrotic diseases, cancers, and cardiovascular and metabolic diseases.

  DOI：

  10.1021/jm100773e
• 作为产物：
  描述：

  1-(2-溴乙氧基)-4-氯苯 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 [2-(4-氯苯氧基)乙基]肼
  参考文献：
  名称：

  单胺氧化酶抑制剂。一系列取代的烷基肼的合成与评估。

  摘要：

  DOI：

  10.1021/jm00337a015

文献信息

• Monoamine Oxidase Inhibitors. The Synthesis and Evaluation of a Series of Substituted Alkylhydrazines
  作者：D. J. Drain、J. G. B. Howes、R. Lazare、Ann M. Salaman、R. Shadbolt、H. W. R. Williams

  DOI：10.1021/jm00337a015

  日期：1963.1
• First in Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis
  作者：Benoı̂t Laleu、Francesca Gaggini、Mike Orchard、Laetitia Fioraso-Cartier、Laurène Cagnon、Sophie Houngninou-Molango、Angelo Gradia、Guillaume Duboux、Cédric Merlot、Freddy Heitz、Cédric Szyndralewiez、Patrick Page

  DOI：10.1021/jm100773e

  日期：2010.11.11

  We describe the design, synthesis, and optimization of first-in-class series of inhibitors of NADPH oxidase isoform 4 (Nox4), an enzyme implicated in several pathologies, in particular idiopathic pulmonary fibrosis, a life-threatening and orphan disease. Initially, several moderately potent pyrazolopyridine dione derivatives were found during a high-throughput screening campaign. SA R investigation around the pyrazolopyridine dione core led to the discovery of several double-digit nanomolar inhibitors in cell free assays of reactive oxygen species (ROS) production, showing high potency on Nox4 and Nox1. The compounds have little affinity for Nox2 isoform and are selective for Nox4/1 isoforms. The specificity of these compounds was confirmed in an extensive in vitro pharmacological profile, as well as in a counterscreening assay for potential ROS scavenging. Concomitant benefits are good oral bioavailability and high plasma concentrations in vivo, allowing further clinical trials for the potential treatment of fibrotic diseases, cancers, and cardiovascular and metabolic diseases.